A trained hematologist and immunogeneticist, Dr. Claude Perreault is one of the founding members of the IRIC and Principal Investigator at the institute since 2005. In addition to his research and training activities, he is a practicing clinician at the Hôpital Maisonneuve-Rosemont where he created the Histocompatibility Laboratory and founded the Bone Marrow Transplant Unit.
Why Choosing Breast Cancer?
The first reason is that breast cancer has a symbolic value and it represents a challenge. In fact the Ebers Papyrus, the oldest maintained medical document written in the XVIth century BC, contains the first description of a cancer, which happens to be breast cancer. Under the heading “Treatment” it states that nothing can be done about this illness. The second reason, of course, is that breast cancer has such an enormous impact, both because of its frequent occurrence and because it affects women of all ages.
A Scientific Accomplishment You Are Proud of
Having discovered the antigenic targets for leukemia immunotherapy. We have developed a completely new method for discovering these antigens, identified enough antigens to treat all patients, and in 2016 we will begin a multicentre study based on these antigens.
- Etiology (causes)
- Screening, diagnosis or prognosis
- The development of scientific models
2009 – Murray Margarit Memorial Award, Leukemia & Lymphoma Society of Canada
2004 – Canada Research Chair in Immunobiology
2011 – The Prix Léo-Pariseau from the Acfas
2015 – The Prix Michel-Sarrazin from the Club de recherches cliniques du Québec
Projects Funded by the Foundation
2015 – The immunopeptidome of breast cancer cells